HIV-1 reverse transcriptase and Hepatitis B virus reverse transcriptase (HIV-1 RT and HBV RT)

HIV-1 reverse transcriptase and Hepatitis B virus reverse transcriptase are closely related viral enzymes critical for the life cycles of retroviruses (HIV-1) and hepadnaviruses (HBV)[3][7]. Reverse transcriptase catalyzes the transcription of viral single-stranded RNA into double-stranded DNA, enabling integration into the host genome, a fundamental step for viral replication. HIV-1 reverse transcriptase is a heterodimer (p66 and p51 subunits) with DNA polymerase and RNase H activities, while HBV reverse transcriptase resembles a multifunctional polymerase that also mediates protein priming and is essential for HBV DNA synthesis from the pregenomic RNA template[1][6][9]. Both enzymes are major therapeutic targets: inhibition with nucleos(t)ide analogs forms the backbone of antiretroviral therapy for HIV and of antiviral therapy for chronic HBV infection[4][8]. Drug resistance arises via mutations in the RT gene, making genetic surveillance and combination therapy crucial for maintaining efficacy[2][5][6]. No single entity labeled “HIV-1 and HBV reverse transcriptase” exists; rather, these are two distinct but homologous viral enzymes with overlapping drug susceptibilities and mechanisms. Note: The query “HIV-1 and HBV reverse transcriptase” is not a single canonical target but rather refers collectively to two separate viral reverse transcriptases. Each has distinct sequence, structure, and drug resistance profiles, though they share mechanistic and pharmacological similarities. Thus, the target entry as stated is not singularly correct for strict database curation: a proper approach is to separate “HIV-1 reverse transcriptase” and “Hepatitis B virus reverse transcriptase” for maximum accuracy.

Other names

HIV-1 RTHuman immunodeficiency virus type-1 reverse transcriptaseHBV RTHepatitis B virus polymerase (contains RT domain)Hepadnaviral reverse transcriptaseRetroviral reverse transcriptase

Inhibition of reverse transcriptase activity by chain termination (NRTIs)[6][4]; Non-competitive inhibition of reverse transcriptase (NNRTIs); Inhibition of DNA polymerization and/or RNase H activity; Prevention of viral genome integration by blocking DNA synthesis